Docoh
Loading...

36 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PRPO Precipio Inc
12 Aug 21
Quarterly report
4:07pm
. Functioning side-by-side as a CLIA operating laboratory, the Omaha facility is designed to expand our proficiencies and know-how in transitioning R&D lab … our HemeScreen technology from the R&D facility to the commercial laboratory setting launching the HemeScreen Reagent Rental (HSRR) program. HSRR
10-Q
2021 Q1
PRPO Precipio Inc
14 May 21
Quarterly report
4:01pm
laboratory, the Omaha facility is designed to expand our proficiencies and know-how in transitioning R&D lab generated technology into a commercial … laboratory environment. Capitalizing on this strategy, during the end of the third quarter 2020, we transitioned our HemeScreen technology from the R&D facility
DEF 14A
PRPO Precipio Inc
29 Apr 21
Definitive proxy
4:31pm
Carl R. Iberger,(4) Chief Financial Officer Ahmed Zaki Sabet,(5) Chief Operations Officer Ayman A. Mohamed,(6) VP R&D The amounts in this column … was appointed our VP R&D effective June 29, 2017. Prior to that, Mr. Mohamed was the Chief Technology Officer of Precipio Diagnostics, Inc. since November
424B5
PRPO Precipio Inc
2 Apr 21
Prospectus supplement for primary offering
2:00pm
to process a variety of commercial molecular tests previously referenced out and to further expand our capabilities and “know-how” in transitioning R&D lab
10-K
2020 FY
PRPO Precipio Inc
29 Mar 21
Annual report
4:29pm
to process a variety of commercial molecular tests previously referenced out and to further expand our capabilities and “know-how” in transitioning R&D lab … commercial lab is to serve as an incubator for our R&D center to design, develop and test new technologies. The Company recognizes the importance
8-K
EX-99.1
PRPO Precipio Inc
16 Oct 18
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
4:41pm
a broader offering to hospitals and laboratories treating cancer patients. Precipio’s R&D team remains on track to release additional products throughout
8-K
PRPO Precipio Inc
9 Aug 18
Precipio Appoints New Board Member to Replace Departing Director
4:31pm
, effective as of that date (the “Mohamed Employment Agreement”), in connection with his existing role as SVP R&D and Laboratory Operations of the Company
8-K
EX-10.1
PRPO Precipio Inc
9 Aug 18
Precipio Appoints New Board Member to Replace Departing Director
4:31pm
with the Company, perform the duties of VP R&D and shall perform such other duties as shall be specified and designated from time to time by the Chief
S-1
PRPO Precipio Inc
15 Apr 18
IPO registration
8:00pm
Position with the Company Stephen Miller Chief Commercial Officer Ahmed Zaki Sabet Chief Operating Officer Ayman A. Mohamed SVP R&D and Laboratory … is a founder of Precipio Diagnostics, Inc. and was named Senior Vice President R&D and Laboratory Operations in June 2017 after serving as Vice
10-K
2017 FY
PRPO Precipio Inc
12 Apr 18
Annual report
8:00pm
Operating Officer Ayman A. Mohamed SVP R&D and Laboratory Operations Mr. Miller currently serves as the Chief Commercial Officer of Precipio, joining … since 2011. Mr. Mohamed is a founder of Precipio Diagnostics, LLC and was named Senior Vice President R&D and Laboratory Operations of Precipio, Inc
8-K
EX-99.1
PRPO Precipio Inc
20 Nov 17
Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update
7:00pm
, which has provided the Company runway to accelerate R&D development, transfer those developments into production tests and to build our sales force
8-K
EX-99.1
PRPO Precipio Inc
13 Nov 17
Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as Director
7:00pm
to 2001, Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, including as a vice
8-K
EX-99.1
PRPO Precipio Inc
12 Nov 17
Precipio, Inc. Announces Closing of $2,748,000 Registered Direct Offering
7:00pm
to execute on our business plan. We believe this new financing enables us to make significant investments in the R&D and sales and marketing aspects
8-K
EX-99.1
PRPO Precipio Inc
7 Sep 17
Precipio Provides Shareholder Update Letter
8:00pm
sq. foot facility which housed both its CLIA laboratory testing facility, as well as an R&D facility. We took the pending merger as an opportunity
FWP
PRPO Precipio Inc
1 Aug 17
Free writing prospectus
8:00pm
Growth Capital, R&D Sole Book-Runner Aegis Capital Corp. Target Pricing Week of August 7th, 2017 Executive summary OVERVIEW THE VISION Eradicate … spanning all fields of reference laboratory operations. Ayman Mohamed, VP R&D – 15 years in laboratory product development and assay design, deep
FWP
PRPO Precipio Inc
31 Jul 17
Free writing prospectus
8:00pm
: Precipio, Inc. Symbol: NASDAQ: PRPO Target Offering: $8.0M Common Stock and Warrants Use of Proceeds: Growth capital, R&D Target Pricing: August 2017 … R&D – 15 years in laboratory product development and assay design, deep understanding of molecular and genetic biology. SCIENTIFIC ADVISORY Jeffrey
8-K
EX-99.1
PRPO Precipio Inc
29 Jun 17
Precipio Diagnostics and Transgenomic Complete Merger
8:00pm
facility costs by more than 75%. The new location is well-suited to serve as the company’s R&D center. To accelerate commercial activities Precipio recently
DEFM14A
PRPO Precipio Inc
11 May 17
Proxy related to merger
8:00pm
. Transgenomic’s lab managers provided an in-depth review of the CLIA and R&D operations of the company. The visit was concluded on Thursday September 1 … financial projections included the following: 2016E 2017E 2018E 2019E 2020E Revenues COGS Gross Profit SG&A & R&D Operating Profit Precipio’s internal
PRER14A
PRPO Precipio Inc
7 May 17
Preliminary revised proxy
8:00pm
projects the company is undertaking. Transgenomic’s lab managers provided an in-depth review of the CLIA and R&D operations of the company. The visit … in this section. Transgenomic’s internal financial projections included the following: 2016E 2017E 2018E 2019E 2020E Revenues COGS Gross Profit SG&A & R&D Operating
PRER14A
PRPO Precipio Inc
23 Apr 17
Preliminary revised proxy
8:00pm
, and the current projects the company is undertaking. Transgenomic’s lab managers provided an in-depth review of the CLIA and R&D operations of the company … : 2016E 2017E 2018E 2019E 2020E Revenues COGS Gross Profit SG&A & R&D Operating Profit Precipio’s internal financial projections included the following